{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:49:40Z","timestamp":1771015780527,"version":"3.50.1"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Salix Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1002\/2327-6924.12387","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T12:20:43Z","timestamp":1469017243000},"page":"393-404","source":"Crossref","is-referenced-by-count":32,"title":["Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations"],"prefix":"10.1097","volume":"28","author":[{"given":"Brian E.","family":"Lacy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie C.","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-9-20210303","first-page":"S1","article-title":"An evidencebased systematic review on the management of irritable bowel syndrome.","volume":"104","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"R2-9-20210303","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","article-title":"Food elimination based on IgG antibodies in irritable bowel syndrome: A randomised controlled trial.","volume":"53","author":"Atkinson","year":"2004","journal-title":"Gut"},{"issue":"6","key":"R3-9-20210303","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cgh.2009.02.023","article-title":"A very lowcarbohydrate diet improves symptoms and quality of life in diarrheapredominant irritable bowel syndrome.","volume":"7","author":"Austin","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"17","key":"R4-9-20210303","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJMra1207068","article-title":"Peripheral mechanisms in irritable bowel syndrome.","volume":"367","author":"Camilleri","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"R5-9-20210303","doi-asserted-by":"crossref","first-page":"G1075","DOI":"10.1152\/ajpgi.00537.2011","article-title":"Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. American Journal of Physiology.","volume":"302","author":"Camilleri","year":"2012","journal-title":"Gastrointestinal and Liver Physiology"},{"issue":"12","key":"R6-9-20210303","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/j.1365-2036.2004.02001.x","article-title":"Irritable bowel syndromeAn evidencebased approach to diagnosis.","volume":"19","author":"Cash","year":"2004","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"5","key":"R7-9-20210303","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1572-0241.2006.00459.x","article-title":"Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and postmarketing surveillance data.","volume":"101","author":"Chang","year":"2006","journal-title":"American Journal of Gastroenterology"},{"issue":"5","key":"R8-9-20210303","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jcph.442","article-title":"Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.","volume":"55","author":"Davenport","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"R10-9-20210303","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2013.04.006","article-title":"Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.","volume":"145","author":"Dove","year":"2013","journal-title":"Gastroenterology"},{"issue":"6","key":"R12-9-20210303","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1053\/gast.2002.37095","article-title":"AGA technical review on irritable bowel syndrome.","volume":"123","author":"Drossman","year":"2002","journal-title":"Gastroenterology"},{"issue":"7","key":"R13-9-20210303","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s10620-009-0792-6","article-title":"A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity.","volume":"54","author":"Drossman","year":"2009","journal-title":"Digestive Diseases and Sciences"},{"issue":"9","key":"R14-9-20210303","first-page":"523","article-title":"The intestinal microbiota and chronic disorders of the gut. Nature Reviews.","volume":"8","author":"DuPont","year":"2011","journal-title":"Gastroenterology Hepatology"},{"issue":"2","key":"R15-9-20210303","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14656566.2011.546347","article-title":"Biologic properties and clinical uses of rifaximin.","volume":"12","author":"DuPont","year":"2011","journal-title":"Expert Opinion Pharmacotherapy"},{"issue":"10","key":"R16-9-20210303","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/apt.12728","article-title":"Review article: Evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets.","volume":"39","author":"DuPont","year":"2014","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"8","key":"R17-9-20210303","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2036.2004.01929.x","article-title":"Systemic review: Natural history of irritable bowel syndrome.","volume":"19","author":"ElSerag","year":"2004","journal-title":"Alimentary Pharmacology Therapeutics"},{"key":"R18-9-20210303","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3389\/fphar.2012.00127","article-title":"Braingut interactions in IBS.","volume":"3","author":"Fichna","year":"2012","journal-title":"Frontiers in Pharmacology"},{"issue":"7","key":"R19-9-20210303","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5HT3 antagonists and 5HT4 agonists in irritable bowel syndrome: Systematic review and metaanalysis.","volume":"104","author":"Ford","year":"2009","journal-title":"American Journal of Gastroenterology"},{"issue":"Suppl 1","key":"R20-9-20210303","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/ajg.2014.187","article-title":"Task force on the management of functional bowel disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation.","volume":"109","author":"Ford","year":"2014","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"R21-9-20210303","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/ajg.2014.202","article-title":"Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: Systematic review and metaanalysis.","volume":"109","author":"Ford","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"R22-9-20210303","doi-asserted-by":"crossref","first-page":"e5836","DOI":"10.1136\/bmj.e5836","article-title":"Irritable bowel syndrome.","volume":"345","author":"Ford","year":"2012","journal-title":"BMJ"},{"issue":"3","key":"R23-9-20210303","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1136\/gut.44.3.400","article-title":"The role of psychological and biological factors in postinfective gut dysfunction.","volume":"44","author":"Gwee","year":"1999","journal-title":"Gut"},{"issue":"1","key":"R24-9-20210303","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome.","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"issue":"78","key":"R25-9-20210303","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3109\/00365521.2011.574729","article-title":"Irritable bowel syndrome patients perspectives on their relationships with healthcare providers.","volume":"46","author":"Halpert","year":"2011","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"5","key":"R26-9-20210303","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11894-009-0058-7","article-title":"Serotonin and the GI tract.","volume":"11","author":"Hasler","year":"2009","journal-title":"Current Gastroenterology Reports"},{"issue":"13","key":"R27-9-20210303","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.regpep.2009.03.012","article-title":"Opioid receptors in the gastrointestinal tract.","volume":"155","author":"Holzer","year":"2009","journal-title":"Regulatory Peptides"},{"issue":"11","key":"R28-9-20210303","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2036.2005.02463.x","article-title":"Irritable bowel syndrome in the United States: Prevalence, symptom patterns and impact.","volume":"21","author":"Hungin","year":"2005","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"39","key":"R30-9-20210303","doi-asserted-by":"crossref","first-page":"14105","DOI":"10.3748\/wjg.v20.i39.14105","article-title":"Irritable bowel syndrome: A microbiomegutbrain axis disorder?","volume":"20","author":"Kennedy","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"6","key":"R31-9-20210303","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/SGA.0000000000000056","article-title":"Clinical pearls for irritable bowel syndrome: Management of the diarrheapredominant subtype.","volume":"37","author":"Lacy","year":"2014","journal-title":"Gastroenterology Nursing: The Official Journal of the Society of Gastroenterology Nurses and Associates"},{"issue":"1","key":"R32-9-20210303","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cgh.2011.08.015","article-title":"Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization.","volume":"10","author":"Ladabaum","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"27","key":"R33-9-20210303","first-page":"8886","article-title":"Intestinal microbiota in pathophysiology and management of irritable bowel syndrome.","volume":"20","author":"Lee","year":"2014","journal-title":"World Journal of Gastroenterology"},{"issue":"16","key":"R34-9-20210303","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMra1403772","article-title":"Clostridium difficile infection.","volume":"372","author":"Leffler","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"R36-9-20210303","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa1505180","article-title":"Eluxadoline for irritable bowel syndrome with diarrhea.","volume":"374","author":"Lembo","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1112","key":"R37-9-20210303","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/j.1365-2036.2004.02267.x","article-title":"Metaanalysis: The treatment of irritable bowel syndrome.","volume":"20","author":"LesbrosPantoflickova","year":"2004","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"9","key":"R38-9-20210303","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time.","volume":"32","author":"Lewis","year":"1997","journal-title":"Scandinavian Journal of Gastroenterology"},{"issue":"5","key":"R39-9-20210303","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders.","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"issue":"3","key":"R40-9-20210303","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1572-0241.2003.07296.x","article-title":"Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective.","volume":"98","author":"Longstreth","year":"2003","journal-title":"American Journal of Gastroenterology"},{"issue":"7","key":"R42-9-20210303","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cgh.2012.02.029","article-title":"Global prevalence of and risk factors for irritable bowel syndrome: A metaanalysis.","volume":"10","author":"Lovell","year":"2012","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"key":"R43-9-20210303","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1038\/ctg.2015.21","article-title":"The effect of dietary intervention on irritable bowel syndrome: A systematic review.","volume":"6","author":"Moayyedi","year":"2015","journal-title":"Clinical and Translational Gastroenterology"},{"issue":"6","key":"R44-9-20210303","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/SGA.0000000000000073","article-title":"The benefits of a nurseled service in the identification and management of symptoms of irritable bowel syndrome.","volume":"37","author":"Moore","year":"2014","journal-title":"Gastroenterology Nursing: The Official Journal of the Society of Gastroenterology Nurses and Associates"},{"key":"R45-9-20210303","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/bmj.300.6722.439","article-title":"Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate.","volume":"300","author":"ODonnell","year":"1990","journal-title":"British Medical Journal"},{"issue":"6","key":"R46-9-20210303","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/j.1572-0241.2008.01869.x","article-title":"Gastrointestinal microbiota in irritable bowel syndrome: Their role in its pathogenesis and treatment.","volume":"103","author":"Parkes","year":"2008","journal-title":"American Journal of Gastroenterology"},{"issue":"1","key":"R47-9-20210303","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1004409","article-title":"Rifaximin therapy for patients with irritable bowel syndrome without constipation.","volume":"364","author":"Pimentel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"R48-9-20210303","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10620-011-1728-5","article-title":"Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects.","volume":"56","author":"Pimentel","year":"2011","journal-title":"Digestive Diseases and Sciences"},{"issue":"5","key":"R51-9-20210303","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinthera.2008.05.002","article-title":"Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: A metaanalysis of eight randomized, placebocontrolled, 12week trials.","volume":"30","author":"Rahimi","year":"2008","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"R53-9-20210303","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.gtc.2010.12.011","article-title":"The role of genetics in IBS.","volume":"40","author":"Saito","year":"2011","journal-title":"Gastroenterology Clinics of North America"},{"issue":"8","key":"R54-9-20210303","first-page":"1910","article-title":"The epidemiology of irritable bowel syndrome in North America: A systematic review.","volume":"97","author":"Saito","year":"2002","journal-title":"American Journal of Gastroenterology"},{"issue":"10","key":"R55-9-20210303","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/apt.12735","article-title":"Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: A pooled analysis of randomised, doubleblind, placebocontrolled trials.","volume":"39","author":"Schoenfeld","year":"2014","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"4","key":"R56-9-20210303","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.amjmed.2011.08.026","article-title":"Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.","volume":"125","author":"Shah","year":"2012","journal-title":"American Journal of Medicine"},{"issue":"9","key":"R57-9-20210303","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/apt.12692","article-title":"Evaluating the functional net value of pharmacologic agents in treating irritable bowel syndrome.","volume":"39","author":"Shah","year":"2014","journal-title":"Alimentary Pharmacology Therapeutics"},{"issue":"7","key":"R58-9-20210303","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cgh.2008.02.058","article-title":"Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: Randomized placebocontrolled evidence.","volume":"6","author":"Shepherd","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association"},{"issue":"3","key":"R60-9-20210303","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2169\/internalmedicine.54.2710","article-title":"Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: A metaanalysis.","volume":"54","author":"Tiequn","year":"2015","journal-title":"Internal Medicine"},{"issue":"5","key":"R61-9-20210303","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/1756283X13491798","article-title":"A 9year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.","volume":"6","author":"Tong","year":"2013","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"4","key":"R62-9-20210303","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000362405","article-title":"Medication management of irritable bowel syndrome.","volume":"89","author":"Trinkley","year":"2014","journal-title":"Digestion"}],"container-title":["Journal of the American Association of Nurse Practitioners"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2F2327-6924.12387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/2327-6924.12387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T16:21:40Z","timestamp":1620922900000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01741002-201607000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1002\/2327-6924.12387","relation":{},"ISSN":["2327-6924"],"issn-type":[{"value":"2327-6924","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}